BSGM - BioSig Technologies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

BioSig Technologies, Inc.

54 Wilton Road
2nd Floor
Westport, CT 06880
United States
203-409-5444
http://www.biosig.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees33

Key Executives

NameTitlePayExercisedYear Born
Mr. Kenneth L. Londoner M.B.A., MBAFounder, CEO & Exec. Chairman1.01MN/A1968
Mr. Steven ChaussyChief Financial OfficerN/AN/A1954
Dr. Budimir S. Drakulic Ph.D.Chief ScientistN/AN/A1950
Ms. Lora MikolaitisVP of Admin.N/AN/A1973
Mr. Andrew Gornell BallouVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioSig Technologies, Inc., a medical technology company, engages in developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. The company's first product, PURE EPTM System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. The company has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EPTM System in August 2018. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company has partnership with Albany Molecular Research Inc. for support in undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19 as a standalone treatment or in combination with other anti-viral agents or immune modulators. BioSig Technologies, Inc. was founded in 2009 and is headquartered in Westport, Connecticut.

Corporate Governance

BioSig Technologies, Inc.’s ISS Governance QualityScore as of December 7, 2019 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 5; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.